Clinical Trial: Bevacizumab Combined with Immunochemotherapy versus Immunochemotherapy Alone as First-Line Treatment for HIV-Positive Patients with Stage IV Driver Gene-Negative Non-Small Cell Lung Cancer: A Multicenter, Bidirectional Cohort Study (China)

Posted On: 2026-09-07

China, Sept. 7 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'Bevacizumab Combined with Immunochemotherapy versus Immunochemotherapy Alone as First-Line Treatment for HIV-Positive Patients with Stage IV Driver Gene-Negative Non-Small Cell Lung Cancer: A Multicenter, Bidirectional Cohort Study'. The following are the other relevant details related to the trial:

Registration Number: ChiCTR2600131724

Registration Time: 2026/09/06

Type: Observational study

Primary Sponsor: Nanfang Hospital, Southern Medical University

To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=341786

Published by HT Digital Content Services with permission from Health Daily Digest....

Click here to read full article from source

To read the full article or to get the complete feed from this publication, please Contact Us.

Exclusive

Category

Source

Publication

Location

Clinical Trial: Bevacizumab Combined with Immunochemotherapy versus Immunochemotherapy Alone as First-Line Treatment for HIV-Positive Patients with Stage IV Driver Gene-Negative Non-Small Cell Lung Cancer: A Multicenter, Bidirectional Cohort Study (China)